Cargando…
贝林妥欧单抗联合达沙替尼逆转Ph阳性急性淋巴细胞白血病患者抗CD19 CAR-T细胞治疗后融合基因转阳1例
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Editorial office of Chinese Journal of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593005/ https://www.ncbi.nlm.nih.gov/pubmed/36709158 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2022.08.015 |
| _version_ | 1784815057425661952 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9593005 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Editorial office of Chinese Journal of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95930052022-11-14 贝林妥欧单抗联合达沙替尼逆转Ph阳性急性淋巴细胞白血病患者抗CD19 CAR-T细胞治疗后融合基因转阳1例 Zhonghua Xue Ye Xue Za Zhi 病例报告 Editorial office of Chinese Journal of Hematology 2022-08 /pmc/articles/PMC9593005/ /pubmed/36709158 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2022.08.015 Text en 2022年版权归中华医学会所有 https://creativecommons.org/licenses/by/3.0/This work is licensed under a Creative Commons Attribution 3.0 License. |
| spellingShingle | 病例报告 贝林妥欧单抗联合达沙替尼逆转Ph阳性急性淋巴细胞白血病患者抗CD19 CAR-T细胞治疗后融合基因转阳1例 |
| title | 贝林妥欧单抗联合达沙替尼逆转Ph阳性急性淋巴细胞白血病患者抗CD19 CAR-T细胞治疗后融合基因转阳1例 |
| title_full | 贝林妥欧单抗联合达沙替尼逆转Ph阳性急性淋巴细胞白血病患者抗CD19 CAR-T细胞治疗后融合基因转阳1例 |
| title_fullStr | 贝林妥欧单抗联合达沙替尼逆转Ph阳性急性淋巴细胞白血病患者抗CD19 CAR-T细胞治疗后融合基因转阳1例 |
| title_full_unstemmed | 贝林妥欧单抗联合达沙替尼逆转Ph阳性急性淋巴细胞白血病患者抗CD19 CAR-T细胞治疗后融合基因转阳1例 |
| title_short | 贝林妥欧单抗联合达沙替尼逆转Ph阳性急性淋巴细胞白血病患者抗CD19 CAR-T细胞治疗后融合基因转阳1例 |
| title_sort | 贝林妥欧单抗联合达沙替尼逆转ph阳性急性淋巴细胞白血病患者抗cd19 car-t细胞治疗后融合基因转阳1例 |
| topic | 病例报告 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593005/ https://www.ncbi.nlm.nih.gov/pubmed/36709158 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2022.08.015 |
| work_keys_str_mv | AT bèilíntuǒōudānkàngliánhédáshātìnínìzhuǎnphyángxìngjíxìnglínbāxìbāobáixuèbìnghuànzhěkàngcd19cartxìbāozhìliáohòurónghéjīyīnzhuǎnyáng1lì AT bèilíntuǒōudānkàngliánhédáshātìnínìzhuǎnphyángxìngjíxìnglínbāxìbāobáixuèbìnghuànzhěkàngcd19cartxìbāozhìliáohòurónghéjīyīnzhuǎnyáng1lì AT bèilíntuǒōudānkàngliánhédáshātìnínìzhuǎnphyángxìngjíxìnglínbāxìbāobáixuèbìnghuànzhěkàngcd19cartxìbāozhìliáohòurónghéjīyīnzhuǎnyáng1lì AT bèilíntuǒōudānkàngliánhédáshātìnínìzhuǎnphyángxìngjíxìnglínbāxìbāobáixuèbìnghuànzhěkàngcd19cartxìbāozhìliáohòurónghéjīyīnzhuǎnyáng1lì AT bèilíntuǒōudānkàngliánhédáshātìnínìzhuǎnphyángxìngjíxìnglínbāxìbāobáixuèbìnghuànzhěkàngcd19cartxìbāozhìliáohòurónghéjīyīnzhuǎnyáng1lì |